Azenta, Inc.

Azenta, Inc.(AZTA)股票分析

$34.090

-2.267 (-6.65%)收盘时

Loading chart…
最高
37.368
开盘
36.520
成交量加权均价
34.83
成交量
1.26M
市值
2.81B
最低
33.030
成交额
43.97M
企业价值/息税折旧摊销前利润(TTM)
35.56

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software.

AI 分析 of Azenta, Inc. (AZTA)

卖出

Azenta Inc is not a good buy right now due to a current price of $34.09, which is significantly below the analyst price target of $35, indicating limited upside potential. Additionally, the stock has a low RSI of 31.611, suggesting it is oversold, but the recent 5-day change of -9.62% raises concerns about momentum. The main risk is the ongoing investigation by Rosen Law Firm regarding potential securities claims, which could further impact investor confidence.

估值指标

Azenta, Inc.(AZTA)当前预期市盈率为 29.07,5 年平均预期市盈率为 186.71。

预期市盈率

合理
5 年均值 P/E
186.71
当前P/E
29.07
高估
487.43
低估
-114.00

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
29.69
当前EV/EBITDA
35.56
高估
68.03
低估
-8.64

预期市销率

合理
5 年均值 P/S
4.86
当前P/S
2.51
高估
8.06
低估
1.66

Alphio AI 对 AZTA 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%AZTA

$34.77

情景价格

基

基准

基准 · 50%AZTA

$30.40

情景价格

悲

悲观

悲观 · 25%AZTA

$25.27

情景价格

持有 AZTA 的大户

A

American Capital Management, Inc.

+ 持有AZTA

+1.32%

3个月收益率

事件时间线

2026-08-24 (ET)

08:30:00

Azenta Appoints Martin Madaus as Interim CEO

08:30:00

Company Reaffirms Q4 Total Revenue Guidance

2026-08-04 (ET)

17:00:00

Total Organic Revenue Expected to Decline in Q4 FY2025

17:00:00

Company Expects Organic Revenue Flat to Up 1% for FY2025

17:00:00

Company Q3 Revenue Exceeds Expectations at $161M

资讯

AZTA 常见问题 —— 由 Alphio AI 解答

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software. It operates in the Healthcare sector (SPECIAL INDUSTRY MACHINERY, NEC industry).

Azenta Inc is not a good buy right now due to a current price of $34.09, which is significantly below the analyst price target of $35, indicating limited upside potential. Additionally, the stock has a low RSI of 31.611, suggesting it is oversold, but the recent 5-day change of -9.62% raises concerns about momentum. The main risk is the ongoing investigation by Rosen Law Firm regarding potential securities claims, which could further impact investor confidence.

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易